Navigation Links
Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide
Date:11/25/2013

DUBLIN, November 25, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/q99tkv/ziopharm) has announced the addition of the "Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


The rationale to develop a stable formulation of palifosfamide is strong: it is the active metabolite of ifosfamide, a well-established alkylating chemotherapy agent. Palifosfamide may spare patients from the toxicities of two other inactive ifosfamide metabolites while retaining its anti-tumor activity. A phase III trial of palifosfamide in first line soft tissue sarcoma (PICASSO III) is underway with progression-free survival results expected later this year. In this report, we review the evidence supporting palifosfamide's development, the likelihood of clinical trial success, key regulatory hurdles as well as the commercial opportunity.

Key Topics Covered:

INTRODUCTION

1. Sarcomas
2. Treatment and prognosis of soft tissue sarcoma
3. Treatment of advanced or metastatic soft tissue sarcoma



PALIFOSFAMIDE

1. Palifosfamide as a single-agent
2. Palifosfamide in combination with doxorubicin
3. Phase I
4. Phase II
5. On-going phase III
6. Phase III trial in small cell lung cancer



CLINICAL AND REGULATORY OPINION

1. The rationale supporting the development of palifosfamide
2. Ifosfamide is active in STS: what does this mean for palifosfamide?
3. Phase II trial of palifosfamide suggests antitumor activity
4. Palifosfamide offers a better safety profile than ifosfamide
5. Ziopharm initiate PICASSO III pivotal trial without FDA's SPA
6. The two regulatory approval pathways
7. Is palifosfamide eligible for Accelerated Approval?
8. Is PFS a validated surrogate for overall survival in randomized front-line STS cancer trials?
9. The Votrient Precedent - Full approval based on PFS
10. Will palifosfamide succeed in the PICASSO III trial?
11. Is the MATISSE phase III trial in SCLC likely to succeed?


MARKET OPPORTUNITY

1. Revenue projection in STS
2. Revenue projections in other indications
3. Competitive landscape



CONCLUSION

Companies Mentioned


- Threshold Pharmaceuticals
- Merck KgaA
- Eisai
- Zeltia
- JNJ
- Ariad Pharmaeuticals,Glaxo-Smith Kline



For more information visit http://www.researchandmarkets.com/research/q99tkv/ziopharm

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
2. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
3. Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
4. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
5. European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion
6. Long Term Follow Up Data On WEB Aneurysm Embolization System Demonstrate High Rate Of Stable Occlusion In Difficult To Treat Aneurysms
7. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
10. Maximum-Strength Formulation Offers Highest Concentration and Purity
11. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Footwear Foundation, the national charitable foundation serving the footwear industry, has broken all ... representing more than 130 companies across 23 states during the months of April ...
(Date:4/29/2016)... Georgia (PRWEB) , ... April 29, 2016 , ... On ... rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB ... Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton School of ... Grand Prize of the 2016 Wharton Business Plan Competition —as well as ... Award, and the Committee Award for Most ‘Wow Factor,’ making them the first ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):